News summary

Newsletter text

[Patients enrolled in the Phase II clinical trial of Nuocheng Jianhua's TYK2JH2 allosteric inhibitor ICP-488 for the treatment of psoriasiszyngablockchaingaming, shares rose 3.3 percent in early tradingzyngablockchaingaming.41%] Nuocheng Jianhua Company, a company focusing on the field of biomedicinezyngablockchaingamingShares of companies rose 3.3 percent in early tradingzyngablockchaingaming.41%, reported at HK$5.16, with turnover reaching HK$11.9804 million. The company announced today that its independently developed TYK2JH2 allosteric inhibitor ICP-488 for the treatment of psoriasis has successfully completed patient enrollment. ICP-488 has demonstrated good effectiveness and safety in previous phase 1 studies. This progress has brought new treatment hope to psoriasis patients. Nuocheng Jianhua said it will continue to advance the research and development process of the drug in order to provide effective treatment options for more patients.